Clinical Efficacy Evaluation of a Continuous Glucose Monitoring-Guided Forecasting Algorithm to Mitigate Postbariatric Hypoglycemia: A Randomized Controlled Trial.

Diabetes Technol TherMar 14, 2026 (epub)

Arlette Journeaux, Selina Zbinden, Francesco Prendin et al.

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated whether a continuous glucose monitoring (CGM)-guided forecasting algorithm could reduce postbariatric hypoglycemia during a standardized meal test in 59 people after Roux-en-Y gastric bypass. Participants received 5 g of glucose either at a predictive alert or after plasma glucose fell below 3.0 mmol/L. Hypoglycemia incidence (<3.0 mmol/L) was 31% with predictive alerts and 44% with the control approach (P = 0.30); nadir glucose and time below glucose thresholds also did not differ significantly. The authors concluded that the 5 g preventive dose was insufficient.

Key findings

  • Hypoglycemia incidence (<3.0 mmol/L) was 31% in the intervention group and 44% in the control group (P = 0.30).
  • Nadir glucose and time spent below 3.9 and 3.0 mmol/L did not differ significantly between groups.
  • Extrapolation from previously published glucose dose-response data suggested that a 10 g preventive dose could reduce hypoglycemia incidence to 9%.

Why it matters

Postbariatric hypoglycemia can pose health risks and impair quality of life, while therapeutic options are limited. This trial found no significant benefit from giving 5 g of glucose at a CGM forecasting alert rather than waiting for glucose to fall below the specified threshold. The findings help distinguish the promise of forecasting from evidence of efficacy for this tested dose and approach.

What to keep in mind

The trial assessed a standardized meal test and a 5 g glucose dose; the proposed 10 g effect was based on extrapolation, not a tested intervention.

Source

Published in Diabetes Technol Ther. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.